Giovanni Parmigiani, PhD; Sining Chen, PhD; Edwin S. Iversen, Jr, PhD; Tara M. Friebel, MPH; Dianne M. Finkelstein, PhD; Hoda Anton-Culver, PhD; Argyrios Ziogas, PhD; Barbara L. Weber, MD; Andrea Eisen, MD; Kathleen E. Malone, PhD; Janet R. Daling, PhD; Li Hsu, PhD; Elaine A. Ostrander, PhD; Leif E. Peterson, PhD; Joellen M. Schildkraut, PhD; Claudine Isaacs, MD; Camille Corio, MA; Leoni Leondaridis, MS; Gail Tomlinson, MD; Christopher I. Amos, PhD; Louise C. Strong, MD; Donald A. Berry, PhD; Jeffrey N. Weitzel, MD; Sharon Sand, CCRP; Debra Dutson, MA; Rich Kerber, PhD; Beth N. Peshkin, MS, CGC; David M. Euhus, MD
Because of the expense of testing for mutations in the BRCA1 or BRCA2 gene, programs use models to estimate the probability of a mutation. Parmigiani and colleagues systematically compared the accuracy of 6 publicly available models in 3 population-based samples and 8 samples of high-risk women from genetic counseling clinics. For practical purposes, the 6 models all discriminated well between women with and without BRCA1 or BRCA2 mutations. None of the models has good sensitivity and specificity across a range of validation populations and probability thresholds to refer for mutation testing.
Ann Intern Med. 2007;147(7):441-450. doi:10.7326/0003-4819-147-7-200710020-00002
Domenico Alvaro, MD; Gianpiero Macarri, MD; Maria Grazia Mancino, MD, PhD; Marco Marzioni, MD; MariaConsiglia Bragazzi, MD; Paolo Onori, MD; Stefano Ginanni Corradini, MD, PhD; Pietro Invernizzi, MD, PhD; Antonio Franchitto, PhD; Adolfo F. Attili, MD; Eugenio Gaudio, MD; Antonio Benedetti, MD
The researchers measured insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF) in the serum and biliary fluid of 73 patients referred for endoscopic retrograde cholangiopancreatography, to assess whether these substances help diagnose extrahepatic cholangiocarcinoma. Biliary IGF-I levels were 15- to 20-fold greater in patients with extrahepatic cholangiocarcinoma than in patients with pancreatic cancer or benign biliary diseases, whereas the biliary VEGF concentration was similar in the 3 groups. Measurement of biliary IGF-I may help to differentiate patients with cholangiocarcinoma from those with pancreatic cancer or benign biliary disease.
Ann Intern Med. 2007;147(7):451-459. doi:10.7326/0003-4819-147-7-200710020-00003
David W. Hutton, MS; Daniel Tan, MS; Samuel K. So, MD; Margaret L. Brandeau, PhD
Up to 10% of Asians and Pacific Islanders living in the United States are chronically infected with hepatitis B virus (HBV), and 25% of them will die of HBV-related illness unless treated. Two thirds are unaware of their HBV infection. The authors assessed the incremental cost-effectiveness of alternative strategies for voluntary screening for HBV in Asian and Pacific Islander adults in the United States. Compared with voluntary screening only, 2 proactive screening strategies were cost-effective. The first was to screen everyone and then treat infected persons. The second was to screen everyone, treat infected persons, and ring vaccinate close contacts. Both strategies cost $36 000 to $40 000 per quality-adjusted life-year gained.
Ann Intern Med. 2007;147(7):460-469. doi:10.7326/0003-4819-147-7-200710020-00004
David B. Reuben, MD*
This Update in Geriatric Medicine features 12 articles published in 2006. Topics include endocrinology, supplements for age-related disorders, urology, dementia, and preventive medicine.
Ann Intern Med. 2007;147(7):470-477. doi:10.7326/0003-4819-147-7-200710020-00005
Roger Chou, MD; Amir Qaseem, MD, PhD, MHA; Vincenza Snow, MD; Donald Casey, MD, MPH, MBA; J. Thomas Cross, Jr, MD, MPH; Paul Shekelle, MD, PhD; Douglas K. Owens, MD, MS; for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians and the American College of Physicians/American Pain Society Low Back Pain Guidelines Panel*
Low back pain is the fifth most common reason for all physician visits in the United States. This guideline presents the available evidence for evaluation and management of acute and chronic low back pain in primary care settings. The target audience is all clinicians caring for patients with low (lumbar) back pain of any duration, with or without leg pain. The target patient population is adults with acute and chronic low back pain not associated with major trauma.
Ann Intern Med. 2007;147(7):478-491. doi:10.7326/0003-4819-147-7-200710020-00006
Roger Chou, MD; Laurie Hoyt Huffman, MS
This evidence review assesses the benefits and harms of diverse nonpharmacologic treatments for acute or chronic low back pain with or without leg pain. Therapies with good evidence of moderate efficacy for chronic or subacute low back pain are cognitive-behavioral therapy, exercise, spinal manipulation, and interdisciplinary rehabilitation. For acute low back pain, the only therapy with good evidence of efficacy is superficial heat.
Ann Intern Med. 2007;147(7):492-504. doi:10.7326/0003-4819-147-7-200710020-00007
This evidence review assesses benefits and harms of pharmacologic therapies for acute or chronic low back pain with or without leg pain. Medications with good evidence of short-term effectiveness for low back pain are nonsteroidal anti-inflammatory drugs, acetaminophen, skeletal muscle relaxants (for acute low back pain), and tricyclic antidepressants (for chronic low back pain). Evidence is insufficient to identify one medication with a clear overall net advantage because of complex tradeoffs between benefits and harms.
Ann Intern Med. 2007;147(7):505-514. doi:10.7326/0003-4819-147-7-200710020-00008
Susan M. Domchek, MD; Antonis Antoniou, PhD
In this issue, Parmigiani and colleagues tested the ability of 6 models to discriminate BRCA1 and BRCA2 mutation carriers from noncarriers. According to these researchers, no one type of model is best. However, to avoid underestimating the risk for breast cancer, one must look at both the risk that an individual has a BRCA1 or BRCA2 mutation and the risk that the individual will develop breast cancer. We need to develop better methods for collecting and acknowledging family history while we continue to improve risk models.
Ann Intern Med. 2007;147(7):515-517. doi:10.7326/0003-4819-147-7-200710020-00009
Thalia Margalit, MD
Interview after interview, it is the same pastries, the same information session, the same suits, the same emergency room. Only instead of selling kitchen knives or used cars, I'm selling myself—not only my efficiency, my clinical and research experiences, and my board scores but also my deepest, most personal motivations.
Ann Intern Med. 2007;147(7):518. doi:10.7326/0003-4819-147-7-200710020-00011
Ann Intern Med. 2007;147(7):519. doi:10.7326/0003-4819-147-7-200710020-00012
Ann Intern Med. 2007;147(7):519. doi:10.7326/0003-4819-147-7-200710020-00013
Ann Intern Med. 2007;147(7):519-520. doi:10.7326/0003-4819-147-7-200710020-00014
Ann Intern Med. 2007;147(7):520. doi:10.7326/0003-4819-147-7-200710020-00015
Ann Intern Med. 2007;147(7):520-521. doi:10.7326/0003-4819-147-7-200710020-00016
Ann Intern Med. 2007;147(7):521. doi:10.7326/0003-4819-147-7-200710020-00017
Ann Intern Med. 2007;147(7):521. doi:10.7326/0003-4819-147-7-200710020-00018
Ann Intern Med. 2007;147(7):522. doi:10.7326/0003-4819-147-7-200710020-00019
Ann Intern Med. 2007;147(7):522-523. doi:10.7326/0003-4819-147-7-200710020-00020
Ann Intern Med. 2007;147(7):523. doi:10.7326/0003-4819-147-7-200710020-00021
Ann Intern Med. 2007;147(7):523-524. doi:10.7326/0003-4819-147-7-200710020-00022
Ann Intern Med. 2007;147(7):524. doi:10.7326/0003-4819-147-7-200710020-00023
Ann Intern Med. 2007;147(7):524. doi:10.7326/0003-4819-147-7-200710020-00024
Joshua Latzman, MD
Ann Intern Med. 2007;147(7):517. doi:10.7326/0003-4819-147-7-200710020-00010
Margaret Trexler Hessen, MD
Ann Intern Med. 2007;147(7):ITC10-1. doi:10.7326/0003-4819-147-7-200710020-01010
Ann Intern Med. 2007;147(7):I-38. doi:10.7326/0003-4819-147-7-200710020-00001
Ann Intern Med. 2007;147(7):I-45. doi:10.7326/0003-4819-147-7-200710020-00025
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only